Zhi Tong Cai Jing·2026-03-11 11:16Core Viewpoint - China National Pharmaceutical Group's subsidiary, Chengdu Tianqing Pharmaceutical, has received clinical trial approval from the NMPA for its innovative drug TQB3205, a pan-KRAS inhibitor aimed at treating advanced malignant tumors [1][2] Group 1: Product Development - TQB3205 is an oral pan-KRAS inhibitor that binds with high affinity to various KRAS mutant proteins, inhibiting SOS1-mediated nucleotide exchange and blocking RAS activation, thereby effectively suppressing the proliferation of various KRAS mutant tumor cells [1] - The KRAS gene is the most frequently mutated gene in the RAS family, with approximately 30% of cancer cases associated with RAS gene mutations, and KRAS mutations account for 85% of all RAS mutations, prevalent in pancreatic cancer (90%), colorectal cancer (30%-50%), and non-small cell lung cancer (15%-20%) [1] - Currently, five KRAS inhibitors approved globally only target the G12C mutation subtype, highlighting the need for broader coverage of KRAS mutation subtypes [1][2] Group 2: Market Demand and Strategy - The clinical demand in the KRAS field remains unmet, necessitating the development of pan-KRAS inhibitors that can address a wider range of mutation subtypes [2] - The company aims to accelerate the clinical development of TQB3205 to provide new treatment options for patients with advanced malignant tumors harboring various KRAS mutations [2]